Business Description
Immunome is a US-based cancer drug company focused on developing treatments that target tumors more precisely and with fewer side effects. Its most advanced programs include a Phase 3 drug for a rare connective tissue cancer called desmoid tumors and an early-stage therapy that delivers toxic payloads directly to cancer cells. The company is also working on several earlier-stage treatments designed to attack solid tumors through different biological pathways. Founded in 2006 and headquartered in Bothell, Washington, Immunome is building a broad pipeline aimed at improving outcomes for cancer patients.
